Agentschap Innoveren & Ondernemen
VC Fund
Brussels, Belgium
Agentschap Innoveren & Ondernemen is a government agency, charged with implementing the economic, innovation and enterprise policy.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Agentschap Innoveren & Ondernemen invests in
Stages Agentschap Innoveren & Ondernemen invests in
Countries Agentschap Innoveren & Ondernemen invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Grant
- $233k–$3.2M
- Pre-Seed
- $106k–$2.2M
Investment Focus
Industry
- Biotechnology 17 (34%)
- Health Care 10 (20%)
- Software 7 (14%)
- Medical 5 (10%)
- Therapeutics 5 (10%)
Country
- Belgium 36 (72%)
- Italy 1 (2%)
- Israel 1 (2%)
- Germany 1 (2%)
- Switzerland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
An Beazar
Member of innovation juries
|
Member of innovation juries | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Protealis
|
Sustainable plant proteins for Europe | $1.3M / Grant / Nov 06, 2024 | |
Exalate
|
Stop copying data! With Exalate it’s simple to connect and sync issue information between different JIRA's.While working in your own environment, information is automatically and securely synced so you can benefit from a unified view and an integrated workflow!Exalate is the most flexible and reliable sync solution while the autonomy ofeach system is preserved. | $201.3K / Grant / Sep 10, 2024 | |
Confo Therapeutics
|
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $1.7M / Grant / Mar 28, 2024 | |
MICLEDI Microdisplays
|
MICLEDI Microdisplays is an experienced executive in the semiconductor industry, | Grant / Mar 12, 2024 | |
AstriVax
|
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $3.2M / Grant / Dec 12, 2023 | |
ExeVir Bio
|
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinicallyvalidated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access.ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium. | $1.7M / Grant / Jun 28, 2023 | |
Flamingo Therapeutics
|
Flamingo Therapeutics is pioneering RNA-targeted therapies for oncology. | $1.9M / Grant / Jun 15, 2023 | |
Stellar Labs
|
At Stellar Labs, we're disrupting Workplace Learning with our groundbreaking AI-Designer and Skillbuilder. Our unique approach, powered by the neuroscience-based GEAR methodology, is designed to transform professional learning making it more efficient, engaging, and effective than ever before. Key Features:- Rapid Design & Delivery:Our AI-driven design allows learning experiences to be created in minutes and launched in days, not months. This agility ensures that your organisation can quickly adapt to new challenges and opportunities.- Evidence-based learning: Leveraging the latest neuroscience, our platform ensures that all training is optimised for maximum knowledge retention and real-world application.- Adaptive Learning Paths: AI personalisation tailors the learning experience to each individual, increasing engagement, performance and productivity.- Measurable Results: Focused on delivering tangible results, we provide insight into performance improvements and productivity gains across your workforce.Stellar Labs isn't just about delivering content; it's about creating a learning culture that adapts, evolves and grows with your organisation. Our platform is designed to improve performance and productivity where it matters most, ensuring your team is equipped with the skills they need for the future.With Stellar Labs, you empower your workforce, accelerate skill acquisition and unlock unprecedented levels of performance and productivity. | $1.5M / Angel / Jun 01, 2023 | |
|
AstriVax
|
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $2.7M / Grant / May 30, 2023 | |
WeHave
|
A GDPR-compliant data-sharing solution that gives eCommerce stores access to accurate customer data for personalization, from the very first interaction. Personalization boosts user experience, conversion and lowers the CAC. At the same time we enable consumers to regain control of their data. WeHave solves the personalization - privacy paradox. | $200K / Pre-Seed / Apr 09, 2023 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Agentschap Innoveren & Ondernemen invest in?
Agentschap Innoveren & Ondernemen invests primarily in Biotechnology, Health Care and Software startups, most often at Grant and Pre-Seed stage. Most of the 50 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Agentschap Innoveren & Ondernemen's check size?
Agentschap Innoveren & Ondernemen typically joins rounds of $233k–$3.2M at Grant and $106k–$2.2M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Agentschap Innoveren & Ondernemen participates in.
How do I contact Agentschap Innoveren & Ondernemen?
Public channels for Agentschap Innoveren & Ondernemen include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Agentschap Innoveren & Ondernemen?
The team at Agentschap Innoveren & Ondernemen includes An Beazar (Member of innovation juries). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
